Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2025)
Aardvark Therapeutics (AARD) reported Net Equity Issued and Repurchased of $195000.0 for Q4 2025, up 100.23% on a YoY basis from $97388.3 in Q4 2024, and up 100.23% sequentially from -$85.0 million in Q4 2024.
Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $195000.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 100.23% year-over-year to $195000.0; the trailing twelve-month figure through Dec 2025 stood at -$84.8 million (changed N/A YoY), and the FY2025 full-year result was $195000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased rose to $195000.0 in Q4 2025, from -$85.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $195000.0 in Q4 2025 to a low of -$85.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -85.00 Mn |
| Dec 31, 2024 | -85.00 Mn |